Emerging antibody-drug conjugates for treating lymphoid malignancies.

about

Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy.

P2860

Q47307286-F5E77BA4-31AE-4255-B2D2-AF643115DCC1

P2860

Emerging antibody-drug conjugates for treating lymphoid malignancies.

Item

http://www.wikidata.org/entity/Q38632313

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Emerging antibody-drug conjugates for treating lymphoid malignancies.

@en

type

Item

label

Emerging antibody-drug conjugates for treating lymphoid malignancies.

@en

prefLabel

Emerging antibody-drug conjugates for treating lymphoid malignancies.

@en

P1476

Emerging antibody-drug conjugates for treating lymphoid malignancies.

@en

P2093

Anna Wolska-Washer

http://www.w3.org/2001/XMLSchema#string

Pawel Robak

http://www.w3.org/2001/XMLSchema#string

Piotr Smolewski

http://www.w3.org/2001/XMLSchema#string

Tadeusz Robak

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody-drug conjugates--an emerging class of cancer treatment

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

Trastuzumab emtansine for HER2-positive advanced breast cancer.

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

Fc receptor-like molecules

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

P304

1-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14728214.2017.1366447

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28792782

http://www.w3.org/2001/XMLSchema#string

Emerging antibody-drug conjugates for treating lymphoid malignancies.

about

P2860

P2860

Emerging antibody-drug conjugates for treating lymphoid malignancies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P577

P698